We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Peripheral neuropathy: zalcitabine reassessed.
- Authors
Carey, Peter; Carey, P
- Abstract
Given that the long-term medical management of HIV infection necessitates making best use of all available antiretrovirals, it is somewhat surprising that the nucleoside analogue reverse transcriptase inhibitor (NRTI) zalcitabine is less commonly used. This may be due to the potential for peripheral neuropathy (PN) which has been associated with the use of this drug. The perception that zalcitabine is poorly tolerated appears to have arisen largely from the results of early monotherapy trials in patients with AIDS and low CD4 cell counts. In contrast, results of more recent studies show that PN is relatively infrequent when zalcitabine is used in combination with other antiretrovirals in current treatment settings.
- Subjects
HIV infections; NEUROPATHY; ANTIRETROVIRAL agents; NUCLEOSIDES; REVERSE transcriptase; PROTEASE inhibitors; HIV infection complications; PERIPHERAL neuropathy; ZALCITABINE (Drug); ANTI-HIV agents; REVERSE transcriptase inhibitors; THERAPEUTICS
- Publication
International Journal of STD & AIDS, 2000, Vol 11, Issue 7, p417
- ISSN
0956-4624
- Publication type
journal article
- DOI
10.1258/0956462001916128